 |
인쇄하기
취소
|
Lucentis therapy is superior to verteporfin photodynamic therapy
The 2-year results of the ANCHOR clinical trial indicate that Lucentis therapy for age-related macular degeneration (AMD) with new-onset, predominantly classic choroidal neovascularization (CNV) is superior to verteporfin photodynamic therapy (PDT).
The results were published in an international journal Ophthalmology (January 2009 issue).
ANCHOR (ANti-VEGF Antibody for the Treatment of Pr...
The results were published in an international journal Ophthalmology (January 2009 issue).
ANCHOR (ANti-VEGF Antibody for the Treatment of Pr...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.